CLTB

Across TCGA pan-cancer cohorts, CLTB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLTB data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLTB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLTB expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where CLTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.933	0.764	.006	19	view →
COAD	DFS	Median	II,III,IV	1.000	0.880	.019	12	view →
CCRCC	OS	Quartile	All	0.833	1.000	.034	4	view →
LUAD	OS	Median	All	0.901	0.988	.033	4	view →
LSCC	DFS	Tertile	All	1.000	0.918	.026	2	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLTB–PDAC (OS)

Open the PDAC breakdown →